Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]
For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]
This article is a run-through of organoids and organs-on-chips in drug discovery! Drug discovery has a […]
Let’s be brutally honest: the traditional event experience is fundamentally broken. It is a relic of […]
On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline […]